GYRE THERAPEUTICS INC (GYRE) Stock Fundamental Analysis
USA - NASDAQ:GYRE - US4037831033 - Common Stock
7.55 USD
+0.06 (+0.8%)
7.55 USD
0 (0%)
Overall GYRE gets a fundamental rating of 5 out of 10. We evaluated GYRE against 533 industry peers in the Biotechnology industry. While GYRE has a great health rating, its profitability is only average at the moment. GYRE is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year GYRE was profitable.
In the past year GYRE had a positive cash flow from operations.
GYRE had negative earnings in 4 of the past 5 years.
In the past 5 years GYRE reported 4 times negative operating cash flow.
1.2 Ratios
GYRE's Return On Assets of 2.73% is amongst the best of the industry. GYRE outperforms 90.43% of its industry peers.
GYRE has a better Return On Equity (4.53%) than 91.37% of its industry peers.
GYRE has a better Return On Invested Capital (5.30%) than 92.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.73% | ||
| ROE | 4.53% | ||
| ROIC | 5.3% |
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 4.08%, GYRE belongs to the top of the industry, outperforming 90.43% of the companies in the same industry.
GYRE's Operating Margin of 9.14% is amongst the best of the industry. GYRE outperforms 91.56% of its industry peers.
With an excellent Gross Margin value of 95.91%, GYRE belongs to the best of the industry, outperforming 95.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.14% | ||
| PM (TTM) | 4.08% | ||
| GM | 95.91% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GYRE is destroying value.
GYRE has more shares outstanding than it did 1 year ago.
GYRE has more shares outstanding than it did 5 years ago.
GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 7.57 indicates that GYRE is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.57, GYRE belongs to the top of the industry, outperforming 80.11% of the companies in the same industry.
GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.57 |
ROIC/WACC0.61
WACC8.74%
2.3 Liquidity
A Current Ratio of 5.40 indicates that GYRE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.40, GYRE is in line with its industry, outperforming 59.10% of the companies in the same industry.
A Quick Ratio of 4.87 indicates that GYRE has no problem at all paying its short term obligations.
The Quick ratio of GYRE (4.87) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.4 | ||
| Quick Ratio | 4.87 |
3. Growth
3.1 Past
GYRE shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.41%.
The Revenue for GYRE has decreased by -64.96% in the past year. This is quite bad
The Revenue has been growing by 78.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-64.96%
Revenue growth 3Y802.05%
Revenue growth 5Y78.95%
Sales Q2Q%19.92%
3.2 Future
The Earnings Per Share is expected to grow by 15.62% on average over the next years. This is quite good.
The Revenue is expected to grow by 98.99% on average over the next years. This is a very strong growth
EPS Next Y590.45%
EPS Next 2Y7.1%
EPS Next 3Y28.26%
EPS Next 5Y15.62%
Revenue Next Year-84.37%
Revenue Next 2Y-41.42%
Revenue Next 3Y186.88%
Revenue Next 5Y98.99%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 58.08, the valuation of GYRE can be described as expensive.
90.81% of the companies in the same industry are more expensive than GYRE, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.45, GYRE is valued quite expensively.
GYRE is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 58.08 | ||
| Fwd PE | N/A |
4.2 Price Multiples
90.62% of the companies in the same industry are more expensive than GYRE, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 53.24 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as GYRE's earnings are expected to grow with 28.26% in the coming years.
PEG (NY)0.1
PEG (5Y)N/A
EPS Next 2Y7.1%
EPS Next 3Y28.26%
5. Dividend
5.1 Amount
GYRE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.55
+0.06 (+0.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners3.78%
Inst Owner Change-9.21%
Ins Owners7.04%
Ins Owner Change0%
Market Cap685.77M
Revenue(TTM)7.34M
Net Income(TTM)4.17M
Analysts84.44
Price Target18.36 (143.18%)
Short Float %13.21%
Short Ratio18.16
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.3%
Min EPS beat(2)-34.64%
Max EPS beat(2)-1.96%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-19.32%
Min Revenue beat(2)-23.85%
Max Revenue beat(2)-14.79%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.26%
PT rev (3m)-10%
EPS NQ rev (1m)-46.66%
EPS NQ rev (3m)-11.1%
EPS NY rev (1m)-20.52%
EPS NY rev (3m)-13.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.99%
Revenue NY rev (1m)-1.32%
Revenue NY rev (3m)-4.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 58.08 | ||
| Fwd PE | N/A | ||
| P/S | 6.71 | ||
| P/FCF | N/A | ||
| P/OCF | 739.77 | ||
| P/B | 7.45 | ||
| P/tB | 7.88 | ||
| EV/EBITDA | 53.24 |
EPS(TTM)0.13
EY1.72%
EPS(NY)-2.45
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.01
OCFY0.14%
SpS1.13
BVpS1.01
TBVpS0.96
PEG (NY)0.1
PEG (5Y)N/A
Graham Number1.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.73% | ||
| ROE | 4.53% | ||
| ROCE | 6.88% | ||
| ROIC | 5.3% | ||
| ROICexc | 8.85% | ||
| ROICexgc | 9.42% | ||
| OM | 9.14% | ||
| PM (TTM) | 4.08% | ||
| GM | 95.91% | ||
| FCFM | N/A |
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 122.05% | ||
| Cap/Sales | 2.49% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 8.12% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.4 | ||
| Quick Ratio | 4.87 | ||
| Altman-Z | 7.57 |
F-Score5
WACC8.74%
ROIC/WACC0.61
Cap/Depr(3y)333.79%
Cap/Depr(5y)313.61%
Cap/Sales(3y)3.51%
Cap/Sales(5y)4.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y590.45%
EPS Next 2Y7.1%
EPS Next 3Y28.26%
EPS Next 5Y15.62%
Revenue 1Y (TTM)-64.96%
Revenue growth 3Y802.05%
Revenue growth 5Y78.95%
Sales Q2Q%19.92%
Revenue Next Year-84.37%
Revenue Next 2Y-41.42%
Revenue Next 3Y186.88%
Revenue Next 5Y98.99%
EBIT growth 1Y-75.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.21%
EBIT Next 3Y-33.44%
EBIT Next 5YN/A
FCF growth 1Y90.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y105.3%
OCF growth 3YN/A
OCF growth 5YN/A
GYRE THERAPEUTICS INC / GYRE FAQ
What is the fundamental rating for GYRE stock?
ChartMill assigns a fundamental rating of 5 / 10 to GYRE.
What is the valuation status of GYRE THERAPEUTICS INC (GYRE) stock?
ChartMill assigns a valuation rating of 3 / 10 to GYRE THERAPEUTICS INC (GYRE). This can be considered as Overvalued.
Can you provide the profitability details for GYRE THERAPEUTICS INC?
GYRE THERAPEUTICS INC (GYRE) has a profitability rating of 5 / 10.
What are the PE and PB ratios of GYRE THERAPEUTICS INC (GYRE) stock?
The Price/Earnings (PE) ratio for GYRE THERAPEUTICS INC (GYRE) is 58.08 and the Price/Book (PB) ratio is 7.45.
What is the earnings growth outlook for GYRE THERAPEUTICS INC?
The Earnings per Share (EPS) of GYRE THERAPEUTICS INC (GYRE) is expected to grow by 590.45% in the next year.